Sujay Krishna Maity
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sujay Krishna Maity has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Partha Chakrabarti
Division of Cell Biology and Physiology, CSIR-Indian Institute of Chemical Biology, Kolkata, India
7 shared publications - Jit Sarkar
Cell Biology and Physiology, CSIR-Indian Institute of Chemical Biology, Kolkata, West Bengal, India
3 shared publications Avishek Paul
Division of Cell Biology and Physiology, Council of Scientific & Industrial Research–Indian Institute of Chemical Biology, Kolkata
2 shared publications- Chittaranjan Mandal
Department of Computer Science and Engineering, Indian Institute of Technology Kharagpur, Kharagpur, India
2 shared publications - Devleena Ghosh
Department of Computer Science and Engineering, Indian Institute of Technology Kharagpur, Kharagpur, India
2 shared publications - Manoja Rajalakshmi Aravindakshan
Affiliation Department of Computer Science and Engineering, Indian Institute of Technology Kharagpur, Kharagpur, West Bengal, India
2 shared publications
Latest Publications
Structure‐Activity‐Based Electrode‐Fibril Interaction and Selective Electrochemical Disassembly of Fibrils via ROS‐Mediated Structural Collapse
The pathological aggregation of misfolded proteins into β‐sheet‐rich amyloid fibrils underlies a broad spectrum of debilitating diseases, yet strategies capable of effectively reversing these supramolecular assemblies remain an open challenge. Here, we demonstrate that a selective electrode‐fibril interaction could be achieved by quantifying the ratio of solvent‐exposed hydrophobic to polar residues. The interaction between insulin fibrils and graphite electrodes, compared to platinum, facilitates localization and selective degradation of β‐sheet‐rich amyloid fibrils under DC and pulsed‐DC stimulation. Importantly, the higher ratio of solvent‐exposed oxidation‐prone amino acids assists the reactive oxygen species (ROS)‐mediated catalytic oxidation and the selective degradation of insulin fibrils over lysozyme fibrils. Electrochemical stimulation not only disassembles fibrils but also reduces toxicity and restores insulin's biological activity. Overall, our findings highlight the critical roles of electrode‐fibril interaction, surface‐exposed oxidation‐prone amino acids, and proximity‐driven catalytic oxidation in dismantling fibrils, providing a foundation for amyloid‐targeting electrotherapeutics.
Structure‐Activity‐Based Electrode‐Fibril Interaction and Selective Electrochemical Disassembly of Fibrils via ROS‐Mediated Structural Collapse
The pathological aggregation of misfolded proteins into β‐sheet‐rich amyloid fibrils underlies a broad spectrum of debilitating diseases, yet strategies capable of effectively reversing these supramolecular assemblies remain an open challenge. Here, we demonstrate that a selective electrode‐fibril interaction could be achieved by quantifying the ratio of solvent‐exposed hydrophobic to polar residues. The interaction between insulin fibrils and graphite electrodes, compared to platinum, facilitates localization and selective degradation of β‐sheet‐rich amyloid fibrils under DC and pulsed‐DC stimulation. Importantly, the higher ratio of solvent‐exposed oxidation‐prone amino acids assists the reactive oxygen species (ROS)‐mediated catalytic oxidation and the selective degradation of insulin fibrils over lysozyme fibrils. Electrochemical stimulation not only disassembles fibrils but also reduces toxicity and restores insulin's biological activity. Overall, our findings highlight the critical roles of electrode‐fibril interaction, surface‐exposed oxidation‐prone amino acids, and proximity‐driven catalytic oxidation in dismantling fibrils, providing a foundation for amyloid‐targeting electrotherapeutics.
- Open Access
Glucose-dependent regulation of hepatic adipsin controls glucose uptake and tolerance
Complement factor D, also known as adipsin, is produced by adipose tissue, and the liver that links metabolic regulation with innate immunity. Despite its established systemic functions, the regulation of hepatic adipsin expression and its contribution to metabolic disease remain poorly defined. Here, we show that hepatic adipsin protein abundance is markedly increased in individuals with type 2 diabetes (T2D), and positively correlates with glycated hemoglobin, despite unchanged mRNA expression. Concordantly, hepatic adipsin protein levels were elevated in multiple murine models of hyperglycemia, including type 1 diabetes (T1D), T2D, and following fasting refeeding transitions. In cultured hepatocytes, glucose exposure induced a rapid, dose-dependent increase in adipsin protein without altering transcript abundance, demonstrating post-transcriptional regulation. Mechanistically, glucose stimulates adipsin translation via dephosphorylation of eukaryotic initiation factor 2alpha (eIF2alpha), and activation of the mammalian target of rapamycin, mediated by the 5' untranslated region of adipsin mRNA. Functionally, hepatocyte-specific depletion of adipsin impaired postprandial glucose tolerance, with reduced glucose uptake and a marked downregulation of glucose transporter type 2 (GLUT2). Taken together, these findings identify hepatic adipsin as a glucose-responsive translational target that couples nutrient availability to metabolic adaptation, revealing a new layer of regulation with potential relevance to diabetes pathogenesis.
Open AccessGlucose-dependent regulation of hepatic adipsin controls glucose uptake and tolerance
Complement factor D, also known as adipsin, is produced by adipose tissue, and the liver that links metabolic regulation with innate immunity. Despite its established systemic functions, the regulation of hepatic adipsin expression and its contribution to metabolic disease remain poorly defined. Here, we show that hepatic adipsin protein abundance is markedly increased in individuals with type 2 diabetes (T2D), and positively correlates with glycated hemoglobin, despite unchanged mRNA expression. Concordantly, hepatic adipsin protein levels were elevated in multiple murine models of hyperglycemia, including type 1 diabetes (T1D), T2D, and following fasting refeeding transitions. In cultured hepatocytes, glucose exposure induced a rapid, dose-dependent increase in adipsin protein without altering transcript abundance, demonstrating post-transcriptional regulation. Mechanistically, glucose stimulates adipsin translation via dephosphorylation of eukaryotic initiation factor 2alpha (eIF2alpha), and activation of the mammalian target of rapamycin, mediated by the 5' untranslated region of adipsin mRNA. Functionally, hepatocyte-specific depletion of adipsin impaired postprandial glucose tolerance, with reduced glucose uptake and a marked downregulation of glucose transporter type 2 (GLUT2). Taken together, these findings identify hepatic adipsin as a glucose-responsive translational target that couples nutrient availability to metabolic adaptation, revealing a new layer of regulation with potential relevance to diabetes pathogenesis.
- Open Access
- 29 August 2024
- Published by BMJ in BMJ Open Diabetes Research & Care
- Vol. 12 (4) , e004179
Adipose tissue–derived adipsin marks human aging in non-type 2 diabetes population
Introduction Adipsin or complement factor D is an adipokine that augments insulin secretion, is altered in various degrees of obesity, and is involved in alternative complement pathway. However, whether adipsin has any independent association with risk factors and biomarkers in patients with type 2 diabetes (T2D) remains elusive. Research design and methods We performed an oral glucose tolerance test on a subset of 43 patients with T2D from the community health cohort to access the role of adipsin in insulin secretion. We further cross-sectionally examined the role of adipsin in plasma, adipose tissue (AT), and secretion in a community cohort of 353 subjects and a hospital cohort of 52 subjects. Results We found that plasma adipsin has no significant correlation with insulin secretion in people with diabetes. Among the risk factors of T2D, adipsin levels were independently associated only with age, and a positive correlation between plasma adipsin and age among subjects without T2D was lost in patients with T2D. Plasma adipsin levels, AT adipsin expression, and secretion were upregulated both in T2D and aging, with a corresponding drop in Homeostatic Model Assessment for assessing β-cell function. Adipsin expression was positively associated with other aging biomarkers, such as β-galactosidase, p21, and p16. These results also corroborated with existing plasma proteomic signatures of aging, including growth, and differentiation factor-15, which strongly correlated with adipsin. Conclusions Our results demonstrate an increase in circulating adipsin in T2D and aging, and it scores as a candidate plasma marker for aging specifically in non-T2D population.
- 29 August 2024
- Published by BMJ in BMJ Open Diabetes Research & Care
- Vol. 12 (4) , e004179
Open AccessAdipose tissue–derived adipsin marks human aging in non-type 2 diabetes population
Introduction Adipsin or complement factor D is an adipokine that augments insulin secretion, is altered in various degrees of obesity, and is involved in alternative complement pathway. However, whether adipsin has any independent association with risk factors and biomarkers in patients with type 2 diabetes (T2D) remains elusive. Research design and methods We performed an oral glucose tolerance test on a subset of 43 patients with T2D from the community health cohort to access the role of adipsin in insulin secretion. We further cross-sectionally examined the role of adipsin in plasma, adipose tissue (AT), and secretion in a community cohort of 353 subjects and a hospital cohort of 52 subjects. Results We found that plasma adipsin has no significant correlation with insulin secretion in people with diabetes. Among the risk factors of T2D, adipsin levels were independently associated only with age, and a positive correlation between plasma adipsin and age among subjects without T2D was lost in patients with T2D. Plasma adipsin levels, AT adipsin expression, and secretion were upregulated both in T2D and aging, with a corresponding drop in Homeostatic Model Assessment for assessing β-cell function. Adipsin expression was positively associated with other aging biomarkers, such as β-galactosidase, p21, and p16. These results also corroborated with existing plasma proteomic signatures of aging, including growth, and differentiation factor-15, which strongly correlated with adipsin. Conclusions Our results demonstrate an increase in circulating adipsin in T2D and aging, and it scores as a candidate plasma marker for aging specifically in non-T2D population.
- Open Access
Leptin augmented model to include the role of obesity in insulin-glucose regulatory system for T2DM subjects
Leptin is a fat cell-derived hormone involved in satiety and body weight regulation. It also plays a critical regulatory role in the insulin-glucose regulatory system by modulating glucose metabolism and energy homeostasis. However, existing insulin-glucose models often fail to consider the impact of body weight indicators mainly body mass index (BMI) and plasma leptin. To address this limitation, we propose augmenting the ordinary differential equations (ODE) of the Oral Minimal Model (OMM) with an additional equation, incorporating leptin as well as supplementary terms and parameters. By estimating the model parameters, the model behaviour is aligned with the observed data of glucose, insulin and leptin for individuals with type 2 diabetes mellitus (T2DM). Based on model behaviour, revised indices formulated from Oral Glucose Tolerance Test (OGTT) data by including BMI and fasting leptin values are found to have a better correlation with existing indices. Additionally, parameter sensitivity analysis is performed to investigate the influence of the model parameters on the observed variables. Validation of the augmented model with clinical data (without leptin) demonstrates a superior fit to glucose and insulin data compared to the base model. This model emphasizes the intricate associations between leptin, glucose, and insulin concentrations with a potential for developing targeted interventions and therapies for T2DM. Notably, this manuscript introduces the first ODE-based model that incorporates leptin and BMI in the insulin-glucose pathway.
Open AccessLeptin augmented model to include the role of obesity in insulin-glucose regulatory system for T2DM subjects
Leptin is a fat cell-derived hormone involved in satiety and body weight regulation. It also plays a critical regulatory role in the insulin-glucose regulatory system by modulating glucose metabolism and energy homeostasis. However, existing insulin-glucose models often fail to consider the impact of body weight indicators mainly body mass index (BMI) and plasma leptin. To address this limitation, we propose augmenting the ordinary differential equations (ODE) of the Oral Minimal Model (OMM) with an additional equation, incorporating leptin as well as supplementary terms and parameters. By estimating the model parameters, the model behaviour is aligned with the observed data of glucose, insulin and leptin for individuals with type 2 diabetes mellitus (T2DM). Based on model behaviour, revised indices formulated from Oral Glucose Tolerance Test (OGTT) data by including BMI and fasting leptin values are found to have a better correlation with existing indices. Additionally, parameter sensitivity analysis is performed to investigate the influence of the model parameters on the observed variables. Validation of the augmented model with clinical data (without leptin) demonstrates a superior fit to glucose and insulin data compared to the base model. This model emphasizes the intricate associations between leptin, glucose, and insulin concentrations with a potential for developing targeted interventions and therapies for T2DM. Notably, this manuscript introduces the first ODE-based model that incorporates leptin and BMI in the insulin-glucose pathway.
- Open Access
Parameter estimation for the oral minimal model and parameter distinctions between obese and non-obese type 2 diabetes
Oral Glucose Tolerance Test (OGTT) is the primary test used to diagnose type 2 diabetes mellitus (T2DM) in a clinical setting. Analysis of OGTT data using the Oral Minimal Model (OMM) along with the rate of appearance of ingested glucose ( R a ) is performed to study differences in model parameters for control and T2DM groups. The differentiation of parameters of the model gives insight into the behaviour and physiology of T2DM. The model is also studied to find parameter differences among obese and non-obese T2DM subjects and the sensitive parameters were co-related to the known physiological findings. Sensitivity analysis is performed to understand changes in parameter values with model output and to support the findings, appropriate statistical tests are done. This seems to be the first preliminary application of the OMM with obesity as a distinguishing factor in understanding T2DM from estimated parameters of insulin-glucose model and relating the statistical differences in parameters to diabetes pathophysiology. Highlights: An established oral minimal model is used for estimation of parameters obese and non-obese type 2 diabetes. This is a novel attempt to use oral minimal model to co-relate the parameters for different diabetic groups using oral glucose tolerance test (OGTT) data. The data of different diabetes groups were utilised for model parameter determination and through statistical tests, distinctions in parameter distribution were identified. It was observed that obese diabetic group are more insulin resistant compared to non-obese diabetic group.
Open AccessParameter estimation for the oral minimal model and parameter distinctions between obese and non-obese type 2 diabetes
Oral Glucose Tolerance Test (OGTT) is the primary test used to diagnose type 2 diabetes mellitus (T2DM) in a clinical setting. Analysis of OGTT data using the Oral Minimal Model (OMM) along with the rate of appearance of ingested glucose ( R a ) is performed to study differences in model parameters for control and T2DM groups. The differentiation of parameters of the model gives insight into the behaviour and physiology of T2DM. The model is also studied to find parameter differences among obese and non-obese T2DM subjects and the sensitive parameters were co-related to the known physiological findings. Sensitivity analysis is performed to understand changes in parameter values with model output and to support the findings, appropriate statistical tests are done. This seems to be the first preliminary application of the OMM with obesity as a distinguishing factor in understanding T2DM from estimated parameters of insulin-glucose model and relating the statistical differences in parameters to diabetes pathophysiology. Highlights: An established oral minimal model is used for estimation of parameters obese and non-obese type 2 diabetes. This is a novel attempt to use oral minimal model to co-relate the parameters for different diabetic groups using oral glucose tolerance test (OGTT) data. The data of different diabetes groups were utilised for model parameter determination and through statistical tests, distinctions in parameter distribution were identified. It was observed that obese diabetic group are more insulin resistant compared to non-obese diabetic group.
- Open Access
- 29 April 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (9) , 8084
PIMT Controls Insulin Synthesis and Secretion through PDX1
Pancreatic beta cell function is an important component of glucose homeostasis. Here, we investigated the function of PIMT (PRIP-interacting protein with methyl transferase domain), a transcriptional co-activator binding protein, in the pancreatic beta cells. We observed that the protein levels of PIMT, along with key beta cell markers such as PDX1 (pancreatic and duodenal homeobox 1) and MafA (MAF bZIP transcription factor A), were reduced in the beta cells exposed to hyperglycemic and hyperlipidemic conditions. Consistently, PIMT levels were reduced in the pancreatic islets isolated from high fat diet (HFD)-fed mice. The RNA sequencing analysis of PIMT knockdown beta cells identified that the expression of key genes involved in insulin secretory pathway, Ins1 (insulin 1), Ins2 (insulin 2), Kcnj11 (potassium inwardly-rectifying channel, subfamily J, member 11), Kcnn1 (potassium calcium-activated channel subfamily N member 1), Rab3a (member RAS oncogene family), Gnas (GNAS complex locus), Syt13 (synaptotagmin 13), Pax6 (paired box 6), Klf11 (Kruppel-Like Factor 11), and Nr4a1 (nuclear receptor subfamily 4, group A, member 1) was attenuated due to PIMT depletion. PIMT ablation in the pancreatic beta cells and in the rat pancreatic islets led to decreased protein levels of PDX1 and MafA, resulting in the reduction in glucose-stimulated insulin secretion (GSIS). The results from the immunoprecipitation and ChIP experiments revealed the interaction of PIMT with PDX1 and MafA, and its recruitment to the insulin promoter, respectively. Importantly, PIMT ablation in beta cells resulted in the nuclear translocation of insulin. Surprisingly, forced expression of PIMT in beta cells abrogated GSIS, while Ins1 and Ins2 transcript levels were subtly enhanced. On the other hand, the expression of genes, PRIP/Asc2/Ncoa6 (nuclear receptor coactivator 6), Pax6, Kcnj11, Syt13, Stxbp1 (syntaxin binding protein 1), and Snap25 (synaptosome associated protein 25) associated with insulin secretion, was significantly reduced, providing an explanation for the decreased GSIS upon PIMT overexpression. Our findings highlight the importance of PIMT in the regulation of insulin synthesis and secretion in beta cells.
- 29 April 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (9) , 8084
Open AccessPIMT Controls Insulin Synthesis and Secretion through PDX1
Pancreatic beta cell function is an important component of glucose homeostasis. Here, we investigated the function of PIMT (PRIP-interacting protein with methyl transferase domain), a transcriptional co-activator binding protein, in the pancreatic beta cells. We observed that the protein levels of PIMT, along with key beta cell markers such as PDX1 (pancreatic and duodenal homeobox 1) and MafA (MAF bZIP transcription factor A), were reduced in the beta cells exposed to hyperglycemic and hyperlipidemic conditions. Consistently, PIMT levels were reduced in the pancreatic islets isolated from high fat diet (HFD)-fed mice. The RNA sequencing analysis of PIMT knockdown beta cells identified that the expression of key genes involved in insulin secretory pathway, Ins1 (insulin 1), Ins2 (insulin 2), Kcnj11 (potassium inwardly-rectifying channel, subfamily J, member 11), Kcnn1 (potassium calcium-activated channel subfamily N member 1), Rab3a (member RAS oncogene family), Gnas (GNAS complex locus), Syt13 (synaptotagmin 13), Pax6 (paired box 6), Klf11 (Kruppel-Like Factor 11), and Nr4a1 (nuclear receptor subfamily 4, group A, member 1) was attenuated due to PIMT depletion. PIMT ablation in the pancreatic beta cells and in the rat pancreatic islets led to decreased protein levels of PDX1 and MafA, resulting in the reduction in glucose-stimulated insulin secretion (GSIS). The results from the immunoprecipitation and ChIP experiments revealed the interaction of PIMT with PDX1 and MafA, and its recruitment to the insulin promoter, respectively. Importantly, PIMT ablation in beta cells resulted in the nuclear translocation of insulin. Surprisingly, forced expression of PIMT in beta cells abrogated GSIS, while Ins1 and Ins2 transcript levels were subtly enhanced. On the other hand, the expression of genes, PRIP/Asc2/Ncoa6 (nuclear receptor coactivator 6), Pax6, Kcnj11, Syt13, Stxbp1 (syntaxin binding protein 1), and Snap25 (synaptosome associated protein 25) associated with insulin secretion, was significantly reduced, providing an explanation for the decreased GSIS upon PIMT overexpression. Our findings highlight the importance of PIMT in the regulation of insulin synthesis and secretion in beta cells.
- Open Access
- 28 July 2022
- Published by American Diabetes Association in Diabetes
- Vol. 71 (11) , 2284-2296
Liver-Derived S100A6 Propels β-Cell Dysfunction in NAFLD
Nonalcoholic fatty liver disease (NAFLD) is an independent predictor of systemic insulin resistance and type 2 diabetes mellitus (T2DM). However, converse correlates between excess liver fat content and β-cell function remain equivocal. Specifically, how the accumulation of liver fat consequent to the enhanced de novo lipogenesis (DNL) leads to pancreatic β-cell failure and eventually to T2DM is elusive. Here, we have identified that low-molecular-weight calcium-binding protein S100A6, or calcyclin, inhibits glucose-stimulated insulin secretion (GSIS) from β cells through activation of the receptor for the advanced glycation end products and diminution of mitochondrial respiration. Serum S100A6 level is elevated both in human patients with NAFLD and in a high-fat diet–induced mouse model of NAFLD. Although serum S100A6 levels are negatively associated with β-cell insulin secretory capacity in human patients, depletion of hepatic S100A6 improves GSIS and glycemia in mice, suggesting that S100A6 contributes to the pathophysiology of diabetes in NAFLD. Moreover, transcriptional induction of hepatic S100A6 is driven by the potent regulator of DNL, carbohydrate response element-binding protein (ChREBP), and ectopic expression of ChREBP in the liver suppresses GSIS in a S100A6-sensitive manner. Together, these data suggest elevated serum levels of S100A6 may serve as a biomarker in identifying patients with NAFLD with a heightened risk of developing β-cell dysfunction. Overall, our data implicate S100A6 as, to our knowledge, a hitherto unknown hepatokine to be activated by ChREBP and that participates in the hepato-pancreatic communication to impair insulin secretion and drive the development of T2DM in NAFLD.
- 28 July 2022
- Published by American Diabetes Association in Diabetes
- Vol. 71 (11) , 2284-2296
Open AccessLiver-Derived S100A6 Propels β-Cell Dysfunction in NAFLD
Nonalcoholic fatty liver disease (NAFLD) is an independent predictor of systemic insulin resistance and type 2 diabetes mellitus (T2DM). However, converse correlates between excess liver fat content and β-cell function remain equivocal. Specifically, how the accumulation of liver fat consequent to the enhanced de novo lipogenesis (DNL) leads to pancreatic β-cell failure and eventually to T2DM is elusive. Here, we have identified that low-molecular-weight calcium-binding protein S100A6, or calcyclin, inhibits glucose-stimulated insulin secretion (GSIS) from β cells through activation of the receptor for the advanced glycation end products and diminution of mitochondrial respiration. Serum S100A6 level is elevated both in human patients with NAFLD and in a high-fat diet–induced mouse model of NAFLD. Although serum S100A6 levels are negatively associated with β-cell insulin secretory capacity in human patients, depletion of hepatic S100A6 improves GSIS and glycemia in mice, suggesting that S100A6 contributes to the pathophysiology of diabetes in NAFLD. Moreover, transcriptional induction of hepatic S100A6 is driven by the potent regulator of DNL, carbohydrate response element-binding protein (ChREBP), and ectopic expression of ChREBP in the liver suppresses GSIS in a S100A6-sensitive manner. Together, these data suggest elevated serum levels of S100A6 may serve as a biomarker in identifying patients with NAFLD with a heightened risk of developing β-cell dysfunction. Overall, our data implicate S100A6 as, to our knowledge, a hitherto unknown hepatokine to be activated by ChREBP and that participates in the hepato-pancreatic communication to impair insulin secretion and drive the development of T2DM in NAFLD.
- Open Access
- 10 February 2022
- Published by BMJ in BMJ Open Diabetes Research & Care
- Vol. 10 (1) , e002654
Distinct pathoclinical clusters among patients with uncontrolled type 2 diabetes: results from a prospective study in rural India
Introduction Inadequate glycemic control among patients with type 2 diabetes mellitus (T2DM) poses an enormous challenge. Whether this uncontrolled T2DM population is a heterogenous mix of disease subtypes remains unknown. Identification of these subtypes would result in a customized T2DM management protocol thereby paving the way toward personalized therapy. Research design and methods Electronic health records of 339 patients with uncontrolled T2DM patients followed up for a median period of 14 months were analyzed using Uniform Manifold Approximation and Projection followed by density-based spatial clustering of applications with noise. Baseline clinical features and final diagnoses with drug combinations were selected in the analysis. A 30 min oral glucose tolerance test was next performed for assessing the underlying insulin resistance and β cell dysfunction. Results Three major clusters were identified. The first cluster characterized by recent onset T2DM had moderately preserved β cell function. The second cluster with a longer duration of T2DM and associated hypertension showed the best glycemic control with dual antidiabetic therapy. The third cluster with the longest history of T2DM and no history of hypertension had the worst glycemic control in spite of the highest percentage of patients on triple therapy (34.58%) and quadruple therapy (8.41%). Conclusions Uncontrolled T2DM comprises a heterogeneous population with respect to disease duration, presence of co-morbidities and β cell function without significant difference in insulin resistance. Stratifying them on the basis of pathoclinical features is the first step toward a personalized management in T2DM.
- 10 February 2022
- Published by BMJ in BMJ Open Diabetes Research & Care
- Vol. 10 (1) , e002654
Open AccessDistinct pathoclinical clusters among patients with uncontrolled type 2 diabetes: results from a prospective study in rural India
Introduction Inadequate glycemic control among patients with type 2 diabetes mellitus (T2DM) poses an enormous challenge. Whether this uncontrolled T2DM population is a heterogenous mix of disease subtypes remains unknown. Identification of these subtypes would result in a customized T2DM management protocol thereby paving the way toward personalized therapy. Research design and methods Electronic health records of 339 patients with uncontrolled T2DM patients followed up for a median period of 14 months were analyzed using Uniform Manifold Approximation and Projection followed by density-based spatial clustering of applications with noise. Baseline clinical features and final diagnoses with drug combinations were selected in the analysis. A 30 min oral glucose tolerance test was next performed for assessing the underlying insulin resistance and β cell dysfunction. Results Three major clusters were identified. The first cluster characterized by recent onset T2DM had moderately preserved β cell function. The second cluster with a longer duration of T2DM and associated hypertension showed the best glycemic control with dual antidiabetic therapy. The third cluster with the longest history of T2DM and no history of hypertension had the worst glycemic control in spite of the highest percentage of patients on triple therapy (34.58%) and quadruple therapy (8.41%). Conclusions Uncontrolled T2DM comprises a heterogeneous population with respect to disease duration, presence of co-morbidities and β cell function without significant difference in insulin resistance. Stratifying them on the basis of pathoclinical features is the first step toward a personalized management in T2DM.